ES3051337T3 - Glycosylated comp pilin variants, methods of making and uses thereof - Google Patents

Glycosylated comp pilin variants, methods of making and uses thereof

Info

Publication number
ES3051337T3
ES3051337T3 ES19820087T ES19820087T ES3051337T3 ES 3051337 T3 ES3051337 T3 ES 3051337T3 ES 19820087 T ES19820087 T ES 19820087T ES 19820087 T ES19820087 T ES 19820087T ES 3051337 T3 ES3051337 T3 ES 3051337T3
Authority
ES
Spain
Prior art keywords
comp
seq
amino acid
polysaccharide
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19820087T
Other languages
English (en)
Spanish (es)
Inventor
Christian Harding
Mario Feldman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxnewmo LLC
Original Assignee
Vaxnewmo LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxnewmo LLC filed Critical Vaxnewmo LLC
Application granted granted Critical
Publication of ES3051337T3 publication Critical patent/ES3051337T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES19820087T 2018-06-16 2019-06-14 Glycosylated comp pilin variants, methods of making and uses thereof Active ES3051337T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862685970P 2018-06-16 2018-06-16
US201862783971P 2018-12-21 2018-12-21
PCT/US2019/037251 WO2019241672A2 (en) 2018-06-16 2019-06-14 Glycosylated comp pilin variants, methods of making and uses thereof

Publications (1)

Publication Number Publication Date
ES3051337T3 true ES3051337T3 (en) 2025-12-26

Family

ID=68843212

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19820087T Active ES3051337T3 (en) 2018-06-16 2019-06-14 Glycosylated comp pilin variants, methods of making and uses thereof

Country Status (7)

Country Link
US (2) US11932670B2 (enExample)
EP (1) EP3806881B1 (enExample)
JP (2) JP2021528059A (enExample)
AU (1) AU2019287659B2 (enExample)
CA (1) CA3103474A1 (enExample)
ES (1) ES3051337T3 (enExample)
WO (1) WO2019241672A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3039659T3 (en) 2015-02-26 2025-10-23 Vaxnewmo Llc Acinetobacter o-oligosaccharyltransferases and uses thereof
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
JP2021528059A (ja) 2018-06-16 2021-10-21 ヴァックスニューモ エルエルシーＶａｘｎｅｗｍｏ Ｌｌｃ グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用
US12350342B2 (en) 2018-12-21 2025-07-08 Vaxnewmo Llc O-linked glycosylation recognition motifs
WO2021259743A2 (en) * 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Vaccine
US20240066109A1 (en) * 2020-12-31 2024-02-29 Vaxnewmo Llc Klebsiella Pneumoniae O-Antigen Glycosylated Proteins and Methods of Making and Uses Thereof
EP4329796A4 (en) * 2021-04-28 2025-03-19 Vaxnewmo Llc Minimal sequons sufficient for o-linking glycosylation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2671709C (en) 2006-12-13 2016-08-16 The Governors Of The University Of Alberta Methods and systems for o-glycosylating proteins
US20130196410A1 (en) 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
CA2844831A1 (en) 2011-08-12 2013-02-21 The Governors Of The University Of Alberta Method of diagnosing bacterial infections using bacterial glycoproteins
WO2013067523A1 (en) 2011-11-04 2013-05-10 Cornell University A prokaryote-based cell-free system for the synthesis of glycoproteins
ES2905107T3 (es) 2012-10-12 2022-04-07 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
EP3508579B1 (en) 2012-11-07 2021-06-30 GlaxoSmithKline Biologicals SA Production of recombinant vaccine in e. coli by enzymatic conjugation
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
JP6356229B2 (ja) 2013-06-04 2018-07-11 アイコン ジェネティクス ゲーエムベーハー 植物産生糖タンパク質及び組換え糖タンパク質のｎ−グリコシル化部位占有率を調節する方法
US9988426B2 (en) 2014-09-18 2018-06-05 University Of Maryland, Baltimore Broad spectrum conjugate vaccine to prevent Klebsiella pneumoniae and Pseudomonas aeruginosa infections
CN107614679B (zh) 2014-12-30 2026-04-07 葛兰素史密丝克莱恩生物有限公司 用于蛋白糖基化的组合物和方法
ES3039659T3 (en) * 2015-02-26 2025-10-23 Vaxnewmo Llc Acinetobacter o-oligosaccharyltransferases and uses thereof
WO2018135860A1 (ko) 2017-01-17 2018-07-26 포항공과대학교 산학협력단 식물 세포에서의 목적 단백질 발현을 위한 재조합 벡터
EP3492481A1 (en) 2017-11-30 2019-06-05 Vaxxilon AG Vaccine against klebsiella pneumoniae
JP2021528059A (ja) 2018-06-16 2021-10-21 ヴァックスニューモ エルエルシーＶａｘｎｅｗｍｏ Ｌｌｃ グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用
CN113227125A (zh) 2018-12-12 2021-08-06 葛兰素史密丝克莱恩生物有限公司 用于o-连接的糖基化的修饰的载体蛋白
US12350342B2 (en) 2018-12-21 2025-07-08 Vaxnewmo Llc O-linked glycosylation recognition motifs

Also Published As

Publication number Publication date
US12577280B2 (en) 2026-03-17
JP2021528059A (ja) 2021-10-21
US20240262870A1 (en) 2024-08-08
WO2019241672A2 (en) 2019-12-19
US11932670B2 (en) 2024-03-19
AU2019287659B2 (en) 2025-02-20
US20210324017A1 (en) 2021-10-21
EP3806881A2 (en) 2021-04-21
EP3806881B1 (en) 2025-10-08
CA3103474A1 (en) 2019-12-19
WO2019241672A3 (en) 2020-02-06
JP2024079845A (ja) 2024-06-11
AU2019287659A1 (en) 2021-01-07
EP3806881A4 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
ES3051337T3 (en) Glycosylated comp pilin variants, methods of making and uses thereof
ES3055827T3 (en) O-linked glycosylation recognition motifs
WO2017067964A1 (en) P. aeruginosa pcrv-linked antigen vaccines
US20220054632A1 (en) Modified carrier proteins for o-linked glycosylation
US20240066109A1 (en) Klebsiella Pneumoniae O-Antigen Glycosylated Proteins and Methods of Making and Uses Thereof
US20240207383A1 (en) Minimal Sequons Sufficient for O-Linking Glycosylation
CN120897997A (zh) 用于生产具有与第二多肽配偶体的异肽键的糖缀合物多肽的组合物和方法以及这些糖缀合物多肽的用途
JP2025535072A (ja) モラクセラ科ｏ結合型オリゴ糖転移酵素、糖鎖付加断片、及びそれらの使用
EP4452308A1 (en) Vaccine